Lysogene partners with Weizmann Institute

By The Science Advisory Board staff writers

July 1, 2020 -- Lysogene has inked a research agreement with Yeda Research and Development, the commercial arm of the Weizmann Institute of Science, for novel gene therapy.

Through the collaboration, Lysogene and Anthony Futerman, PhD, of the Weizmann Institute will work to develop a novel adeno-associated virus (AAV) gene therapy approach for neuronopathic Gaucher disease, Parkinson's disease, and other diseases associated with mutations of the GBA1 gene.

Under the terms of the agreement, Lysogene will provide expertise in AAV vector design and production, while Futerman's lab will provide glucocerebrosidase variants with enhanced biological properties and conduct proof-of-concept biological studies. Subsequently, Lysogene will have the option to license the program.

Novasep, Lysogene partner for gene therapy
Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter